Fosinopril Prevents the Development of Tactile Allodynia in a Streptozotocin-Induced Diabetic Rat Model.
The aim of this study was to evaluate fosinopril-induced changes in hemodynamic parameters and tactile allodynia in a rat model of diabetes. Diabetes was induced by streptozotocin (STZ; 50 mg/kg, i.p.) in male Wistar rats. STZ produced hyperglycemia, weight loss, polydipsia, polyphagia, and polyuria as well as long-term arterial hypotension, bradycardia, and tactile allodynia at 10-12 weeks. Daily administration of the angiotensin converting enzyme inhibitor, fosinopril (25 mg/kg, p.o., for 11 weeks) partially reduced the loss of body weight, decreased hyperglycemia, and systolic blood pressure in diabetic rats. Likewise, systemic administration of fosinopril prevented the development and maintenance of tactile allodynia in STZ-induced diabetic rats. These data suggest that fosinopril may have a role in the pharmacotherapy of diabetic neuropathic pain.
División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, Mexico.
Claudia Ivonne
CI
Araiza-Saldaña
División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, Mexico.
Erick Fabián
EF
Pedraza-Priego
División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, Mexico.
Jorge Elías
JE
Torres-López
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, México, D.F., Mexico.
Héctor Isaac
HI
Rocha-González
División de Posgrado, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
Gabriela
G
Castañeda-Corral
Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados (Cinvestav), Sede Sur., México, D.F., Mexico.
Enrique
E
Hong-Chong
Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados (Cinvestav), Sede Sur., México, D.F., Mexico.
Vinicio
V
Granados-Soto
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D017328:Fosinopril / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D006930:Hyperalgesia / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D015431:Weight Loss / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D007328:Insulin; D017328:Fosinopril
allodynia; diabetic neuropathy; fosinopril; streptozotocin